FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A fine of the seasons		00540
<i>N</i> ashington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	. 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Berger Heather A.						2. Issuer Name and Ticker or Trading Symbol Design Therapeutics, Inc. [DSGN]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)	(F	rst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023									(give title		Other (sp	1
C/O DESIGN THERAPEUTICS, INC. 6005 HIDDEN VALLEY ROAD, SUITE 110				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person					
(Street)	BAD C	A	92011											Form f Persor		e than	One Repor	ting
(City)	(S	tate)	(Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								nat is intende	d to			
		Tab	le I - Nor	n-Deriv	ative	Sec	curities	Ac	quired, D	ispo	osed o	f, or Be	neficial	ly Owne	d I			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)				Benefici Owned	es Fo ally (D) Following (I)	Form: (D) or	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	tion(s)		(1	Instr. 4)	
		Т							uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise (Instr. 3) Brice of Derivative Security 2. Conversion Date (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year) (Month/Day/Year)			Date,		ransaction of Code (Instr. Deriv			Expiration D	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	ode V (A) (D) Exercisable Date Title					Amount or Number of Shares							
Stock Option (right to buy)	\$5.63	05/31/2023			A		15,000		(1)	05/3	30/2033	Common Stock	15,000	\$0.00	15,000		D	

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

Remarks:

/s/ Mustapha Parekh, Attorney-06/02/2023 in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.